About this trial
To explore the heterogeneity of the development trend of frailty and cognitive function of older adults.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Age ≥60 years.
Older adults with clear consciousness, ability of simple written and verbal communication.
They volunteered to participate in this study, and signed an informed consent.
Disqualifiers
A clear diagnosis of any type of dementia.
There are neurological diseases that clearly lead to cognitive dysfunction, such as severe cerebrovascular disease, brain trauma, intracranial tumors, etc.
They have been clearly diagnosed with mental disorders affecting cognitive function, including schizophrenia, depression, bipolar disorder, etc.
Trial population
Older adults without clear diagnosis of any type of dementia, neurological diseases, and mental disorders that affecting cognitive function.
Trial design
Cohort
Prospective
Treatments tested in this trial
No intervention
Other interventionNo intervention
Treatment groups
Trial outcomes
Primary outcomes
Frailty
Frailty was evaluated by the Fried phenotype model, which was proposed and validated by Fried and colleagues, and is the most widely adopted model, generally regarded as the standard model for physical frailty. In Fried's model, the frailty phenotype is based on the following five components: slowness (gait speed), weakness (hand grip), weight loss, exhaustion, and low physical activity.
Cognitive function
The method to assess objective cognitive function is Montreal Cognitive Assessment-Beijing version for Chinese, which is a classical tool to screen for MCI, including 7 cognitive domains (visuospatial and executive function, naming, attention, language, abstraction, delayed recall, and orientation). The total score of the scale is 30, with higher scores indicating better cognitive function. The Mini-Mental State Examination (MMSE) which included 30 questions to measure the cognitive status will be also performed to assess objective cognitive function. In addition, We use the 9-items subjective cognitive decline questionnaire (SCD-Q9) to measure the symptoms of subjective cognition. The SCD-Q9 is a simple and quick screening scale to identify those who suffer from MCI from general populations. SCD-Q9 lists the 9 core items of SCD symptoms and contains 2 dimensions and 9 items.
Other outcomes
Health status and life style
Data on health status (disease, hearing) and lifestyle (diet, sleep, exercise) of the elderly were obtained through self-made questionnaires.
Activities of daily life (ADLs)
The Chinese version of the ADLs scale revised by Zhang will be utilized to identify the ability to perform the activities. A summary score for each item ranges from 1 (require no help) to 4 (unable to do it at all) points. The first eight items measure Basic Activities of Daily Living (BADLs), with a total score of 8\~32. The last 12 items are about Instrumental Activities of Daily Living (IADLs), with a total score of 12\~48. The lower the score, the lower the degree of dependence on daily life.
Anxiety
General anxiety disorder-7 (GAD-7) will be utilized, which is a seven-question screening tool that identifies whether a complete assessment for anxiety is indicated. Scoring Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively.
Apathy
The apathy subscale (GDS-3A) of the GDS-15 consists of the following three items (score range 0-3 points) will be utilized: (i) Have you dropped many of your activities and interests?; (ii) Do you prefer to stay at home, rather than going out and doing new things?; and (iii) Do you feel full of energy?.
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Zheng Li
Lead sponsor
Peking Union Medical College
Sponsor institution
This trial is not recruiting at the moment. You can still explore other options: